On this page

Aminosyn II

ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, and GLYCINE · Injection, Solution

Prescription NDA Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information.

Overview

Brand name
Aminosyn II
Generic name
ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, and GLYCINE
Dosage form
Injection, Solution
Route
Intravenous
Marketing category
NDA · NDA
Labeler
ICU Medical Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
34
NDC product codes
2
Packages
2
Data completeness
77% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Acetyl L-Tyrosine 270 mg/100mL 800188 —
Acetyl L-Tyrosine 405 mg/100mL 800188 —
Alanine 1490 mg/100mL 800401 View
Alanine 993 mg/100mL 800401 View
Arginine 1018 mg/100mL 800401 View
Arginine 1527 mg/100mL 800401 View
Aspartic Acid 1050 mg/100mL 831426 View
Aspartic Acid 700 mg/100mL 831426 View
Glutamic Acid 1107 mg/100mL 831426 View
Glutamic Acid 738 mg/100mL 831426 View
Glycine 500 mg/100mL 800401 View
Glycine 750 mg/100mL 800401 View
Histidine 300 mg/100mL 800401 View
Histidine 450 mg/100mL 800401 View
Isoleucine 660 mg/100mL 800401 View
Isoleucine 990 mg/100mL 800401 View
Leucine 1000 mg/100mL 800401 View
Leucine 1500 mg/100mL 800401 View
Lysine Acetate 1050 mg/100mL 831426 View
Lysine Acetate 1575 mg/100mL 831426 View
Methionine 172 mg/100mL 800401 View
Methionine 258 mg/100mL 800401 View
Phenylalanine 298 mg/100mL 800401 View
Phenylalanine 447 mg/100mL 800401 View
Proline 1083 mg/100mL 800401 View
Proline 722 mg/100mL 800401 View
Serine 530 mg/100mL 800401 View
Serine 795 mg/100mL 800401 View
Threonine 400 mg/100mL 800401 View
Threonine 600 mg/100mL 800401 View
Tryptophan 200 mg/100mL 800401 View
Tryptophan 300 mg/100mL 800401 View
Valine 500 mg/100mL 800401 View
Valine 750 mg/100mL 800401 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Injection, Solution
Route of administration
Intravenous
Presentations
4

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Amino Acid [EPC] EPC 5 members — no class page
Amino Acids [CS] CS 5 members — no class page

Regulatory status

Source: Drugs@FDANDC Directory
Application number
020041
Application type
NDA · New Drug Application
Approval date
December 19, 1991
Sponsor
OTSUKA ICU MEDCL
Products on application
1
Submissions recorded
13
Products approved under application 020041.
Product Trade name Form Strength Ingredient Status TE Flags
020041-001 AMINOSYN II 15% IN PLASTIC CONTAINER INJECTABLE AMINO ACIDS Prescription —

Approval history

Source: Drugs@FDA
Most recent submissions on application 020041.
Type No. Action Status Date Review
Supplement 20 Manufacturing (CMC) Approved April 27, 2007 N/A
Supplement 13 Manufacturing (CMC) Approved January 27, 2003 Standard
Supplement 12 Manufacturing (CMC) Approved November 8, 2002 Standard
Supplement 11 Labeling Approved August 21, 2002 Standard
Supplement 10 Manufacturing (CMC) Approved May 5, 1997 Standard
Supplement 8 Manufacturing (CMC) Approved March 4, 1997 Standard
Supplement 6 Manufacturing (CMC) Approved August 27, 1996 Standard
Supplement 9 Manufacturing (CMC) Approved August 6, 1996 Standard
Supplement 7 Manufacturing (CMC) Approved August 14, 1995 Standard
Supplement 2 Manufacturing (CMC) Approved April 5, 1995 Standard
Supplement 4 Manufacturing (CMC) Approved July 11, 1994 Standard
Supplement 1 Labeling Approved August 17, 1992 —
Original application 1 Type 3 - New Dosage Form Approved December 19, 1991 Standard

Review documents

  • 0 · Supplement · May 27, 2004
  • 0 · Supplement · August 21, 2002

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251102). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251102

Boxed Warning

openFDA Drug Labeling

Pharmacy Bulk Package – Not For Direct Infusion.

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Aminosyn II, Sulfite-Free, (an amino acid injection) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. SUPPLEMENTAL ELECTROLYTES, IN ACCORDANCE WITH THE PRESCRIPTION OF THE ATTENDING PHYSICIAN, MUST BE ADDED TO AMINOSYN II SOLUTIONS WITHOUT ELECTROLYTES. Aminosyn II can be administered peripherally with dilute (5 to 10%) dextrose solution and I.V. fat emulsion as a source of nutritional support. This form of nutritional support can help to preserve protein and reduce catabolism in stress conditions where oral intake is inadequate. Aminosyn II is also indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where the alimentary tract, by the oral, gastrostomy or jejunostomy route cannot or should not be used and gastrointestinal absorption of protein is impaired.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Each 100 mL of Aminosyn II contains: Amino Acids Nitrogen Aminosyn II 10% 10 g 1.53 g Aminosyn II 15% 15 g 2.30 g The total daily dose of the solution depends on the daily protein requirements and on the patient’s metabolic and clinical response. In many patients, provision of adequate calories in the form of hypertonic dextrose may require the administration of exogenous insulin to prevent hyperglycemia and glycosuria. To prevent rebound hypoglycemia, a solution containing 5% dextrose should be administered when hypertonic dextrose infusions are abruptly discontinued. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. COLOR VARIATION FROM PALE YELLOW TO YELLOW IS NORMAL AND DOES NOT ALTER EFFICACY. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Aminosyn II in the 2000 mL flexible Pharmacy Bulk Package is designed for use with manual, gravity flow operations and automated gravimetric compounding devices for preparing intravenous nutritional admixtures. Admixtures must be stored under refrigeration and used within 24 hours of admixing. Peripheral Vein Nutritional Maintenance A mixture of Aminosyn II and dextrose diluted to a final concentration of 5% to 10% amino acids and 5% to 10% dextrose is suitable for administration by peripheral vein. This solution is not intended for central vein administration because it does not contain adequate amounts of amino acids or electrolytes. For peripheral intravenous infusion, 1 to 1.5 g/kg/day of total amino acids will reduce protein catabolism. Infusion or ingestion of carbohydrate or lipid will not reduce the nitrogen sparing effect of intravenous amino acid infusions at this dose. As with all intravenous fluid therapy, the primary aim is to provide sufficient water to compensate for insensible, urinary and other (nasogastric suction, fistula drainage, diarrhea) fluid losses. Total fluid requirements, as well as electrolyte and acid-base needs, should be estimated and appropriately administered. For an amino acid solution of specified total concentration, the volume required to meet amino acid requirements per 24 hours can be calculated. After making an estimate of the total daily fluid (water) requirement, the balance of fluid needed beyond the volume of amino acid solution required can be provided either as a noncarbohydrate or a carbohydrate-containing electrolyte solution. I.V. lipid emulsion may be substituted for part of the carbohydrate-containing solution. Vitamins and additional electrolytes as needed for maintenance or to correct imbalances may be added to the amino acid solution. If desired, only one-half of an estimated daily amino acid requirement of 1.5 g/kg can be given on the first day. Amino acids together with dextrose in concentrations of 5% to 10% infused into a peripheral vein can be continued while oral nutrition is impaired. However, if a patient is unable to take oral nourishment for a prolonged period of time, institution of total parenteral nutrition with exogenous calories should be considered. Central Vein Total Parenteral Nutrition For central vein infusion with concentrated dextrose solution, alone or with I.V. lipid, the total daily dose of the amino acid solution depends upon daily protein requirements and the patient’s metabolic and clinical response. The determination of nitrogen balance and accurate daily body weights, corrected for fluid balance, are probably the best means of assessing individual protein requirements. ADULTS Solutions containing 3.5 to 5% amino acids with 5 to 10% glucose may be infused with a fat emulsion by peripheral vein to provide approximately 1400 to 2000 kcal/day. Fat emulsion administration should be considered when prolonged parenter …

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS This preparation should not be used in patients with hepatic coma or metabolic disorders involving impaired nitrogen utilization.

WARNINGS Intravenous infusion of amino acids may induce a rise in blood urea nitrogen (BUN), especially in patients with impaired hepatic or renal function. Appropriate laboratory tests should be performed periodically and infusion discontinued if BUN levels exceed normal postprandial limits and continue to rise. It should be noted that a modest rise in BUN normally occurs as a result of increased protein intake. Administration of amino acid solutions to a patient with hepatic insufficiency may result in serum amino acid imbalances, metabolic alkalosis, prerenal azotemia, hyperammonemia, stupor and coma. Administration of amino acid solutions in the presence of impaired renal function may augment an increasing BUN, as does any protein dietary component. Solutions containing sodium ion should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. Solutions which contain potassium ion should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present. Solutions containing acetate ion should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. Hyperammonemia is of special significance in infants, as it can result in mental retardation. Therefore, it is essential that blood ammonia levels be measured frequently in infants. Instances of asymptomatic hyperammonemia have been reported in patients without overt liver dysfunction. The mechanisms of this reaction are not clearly defined, but may involve genetic defects and immature or subclinically impaired liver function. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur even at lower rates of administration.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Peripheral Infusions A 3.5% to 5% solution of amino acids (without additives) is slightly hypertonic. Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation. Electrolyte additives should be spread throughout the day. Irritating additive medications may need to be infused at another venous site. Generalized flushing, fever and nausea also have been reported during peripheral infusions of amino acid solutions.

Drug Interactions

openFDA Drug Labeling

Drug Interactions Because of its antianabolic activity, concurrent administration of tetracycline may reduce the potential effects of amino acids infused with dextrose as part of a parenteral feeding regimen.

Description

openFDA Drug Labeling

DESCRIPTION Aminosyn TM II, Sulfite-Free, (an amino acid injection) is a sterile, nonpyrogenic solution for intravenous infusion. Aminosyn II is oxygen sensitive. The Pharmacy Bulk Package is a sterile dosage form which contains multiple single doses for use only in a pharmacy bulk admixture program. The formulations are described below: Essential Amino Acids (mg/100 mL) Aminosyn II 10% 15% Isoleucine 660 990 Leucine 1000 1500 Lysine (acetate)* 1050 1575 Methionine 172 258 Phenylalanine 298 447 Threonine 400 600 Tryptophan 200 300 Valine 500 750 *Amount cited is for lysine alone and does not include the acetate. Nonessential Amino Acids (mg/100 mL) Alanine 993 1490 Arginine 1018 1527 L-Aspartic Acid 700 1050 L-Glutamic Acid 738 1107 Histidine 300 450 Proline 722 1083 Serine 530 795 N-Acetyl-L-Tyrosine 270 405 Glycine 500 750 Other Characteristics Protein Equivalent (approx. grams/liter) 100 150 Total Nitrogen (grams/liter) 15.3 23.0 Osmolarity (mOsmol/liter, actual) 840 1270 pH a 5.8 (5.0 – 6.5) 5.8 (5.0 – 6.5) Specific Gravity 1.03 1.05 Electrolytes (mEq/L) Sodium (Na + ) b 38 50 Acetate (C 2 H 3 O 2 - ) c 71.8 107.6 a Solution contains sodium hydroxide for pH adjustment. b Figure includes Na + from the pH adjustor. c Includes acetate from lysine acetate. The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The formulas for the individual amino acids are as follows: The Pharmacy Bulk Package is designed for use with manual, gravity flow operations and automated compounding devices for preparing sterile parenteral nutrient admixtures; it contains no bacteriostat. Multiple single doses may be dispensed during continual aliquoting operations. Withdrawal of container contents should be promptly completed within 4 hours after initial closure puncture. structural formula amino acids

OVERDOSAGE In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. (See WARNINGS and PRECAUTIONS .)

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Aminosyn II is supplied as a Pharmacy Bulk Package in a 2000 mL flexible container for continuous admixture compounding procedures. Two concentrations are available: Aminosyn II 10%, Sulfite-Free NDC 0409-7172-17 Aminosyn II 10%, Sulfite-Free NDC 0990-7172-17 Aminosyn II 15%, Sulfite-Free NDC 0409-7171-17 Aminosyn II 15%, Sulfite-Free NDC 0990-7171-17 ICU Medical is transitioning NDC codes from the "0409" to a "0990" labeler code. Both NDC codes are expected to be in the market for a period of time. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Avoid exposure to light. Revised: June, 2018 EN-4657 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA

Shortages

Source: FDA Drug Shortages
Availability records from the FDA Drug Shortages database.
Status Availability Company Presentation Updated
Current Available Otsuka ICU Medical LLC Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17) September 16, 2026
Current Available Otsuka ICU Medical LLC Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17) September 16, 2026

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0990-7171-17 0990-7171 ICU Medical Inc. 6 POUCH in 1 CASE (0990-7171-17) / 1 BAG in 1 POUCH / 2000 mL in 1 BAG November 1, 2019
0990-7172-17 0990-7172 ICU Medical Inc. 6 POUCH in 1 CASE (0990-7172-17) / 1 BAG in 1 POUCH / 2000 mL in 1 BAG November 1, 2019
0990-7171 0990-7171 ICU Medical Inc. — November 1, 2019
0990-7172 0990-7172 ICU Medical Inc. — November 1, 2019

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Drug Labeling FDA / NLM Prescribing information reproduced above
Drug Shortages FDA Supply availability

Generated September 25, 2026 · 10 sections on this page.